MXPA05010068A - Promocion de la angiogenesis por composiciones de prostaglandina y metodos. - Google Patents
Promocion de la angiogenesis por composiciones de prostaglandina y metodos.Info
- Publication number
- MXPA05010068A MXPA05010068A MXPA05010068A MXPA05010068A MXPA05010068A MX PA05010068 A MXPA05010068 A MX PA05010068A MX PA05010068 A MXPA05010068 A MX PA05010068A MX PA05010068 A MXPA05010068 A MX PA05010068A MX PA05010068 A MXPA05010068 A MX PA05010068A
- Authority
- MX
- Mexico
- Prior art keywords
- prostaglandin
- composition
- methods
- micromolar
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion proporciona composiciones y metodos para promover la recuperacion de la funcion vascular en la disfuncion erectil asociada con la vasculopatia, mediante la administracion de una composicion que comprende una protaglandina vasoactiva y un polimero biocompatible. En las modalidades preferidas, la composicion de prostaglandina es una composicion topica que comprende prostaglandina E1, un polimero biocompatible y un mejorador de penetracion, y la composicion topica se aplica al meato en la punta del pene. En otra modalidad, la invencion proporciona un metodo para incrementar el crecimiento exterior microvascular en un segmento arterial objetivo que comprende administrar una composicion de prostaglandina E1 para producir una concentracion de prostaglandina E1 extracelular aproximadamente de 1 micromolar a aproximadamente 10 micromolares adyacente al segmento arterial objetivo durante alrededor de cuatro dias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45660503P | 2003-03-21 | 2003-03-21 | |
PCT/US2004/007981 WO2004084861A2 (en) | 2003-03-21 | 2004-03-16 | Angiogenesis promotion by prostaglandin compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05010068A true MXPA05010068A (es) | 2005-11-23 |
Family
ID=33098132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05010068A MXPA05010068A (es) | 2003-03-21 | 2004-03-16 | Promocion de la angiogenesis por composiciones de prostaglandina y metodos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040241243A1 (es) |
EP (1) | EP1605913A2 (es) |
JP (1) | JP2006520788A (es) |
KR (1) | KR20050119136A (es) |
CN (1) | CN1774237A (es) |
AU (1) | AU2004224459A1 (es) |
CA (1) | CA2519691A1 (es) |
MX (1) | MXPA05010068A (es) |
WO (1) | WO2004084861A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010070617A1 (en) * | 2008-12-19 | 2010-06-24 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
EP4108216A1 (en) | 2009-06-03 | 2022-12-28 | Forsight Vision5, Inc. | Anterior segment drug delivery |
RU2740680C2 (ru) | 2011-09-14 | 2021-01-19 | Форсайт Вижн5, Инк. | Глазное вкладочное устройство и способы |
US9750636B2 (en) | 2012-10-26 | 2017-09-05 | Forsight Vision5, Inc. | Ophthalmic system for sustained release of drug to eye |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
JP2022547532A (ja) * | 2019-09-09 | 2022-11-14 | パシラ・セラピューティクス・インコーポレイテッド | ナトリウムチャネルブロッカーを含む徐放性熱硬化性ゲルおよびそれを製造する方法 |
WO2023048174A1 (ja) * | 2021-09-22 | 2023-03-30 | テイカ製薬株式会社 | 角膜疾患治療剤 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
US5082866A (en) * | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
US4980378A (en) * | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
US6251436B1 (en) * | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US6117949A (en) * | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
US6274159B1 (en) * | 1998-10-28 | 2001-08-14 | University Of Florida | Surface modified silicone drug depot |
US6825234B2 (en) * | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6224573B1 (en) * | 1999-01-15 | 2001-05-01 | Nexmed Holdings, Inc. | Medicament dispenser |
US6118020A (en) * | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
US6323241B1 (en) * | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US6693135B2 (en) * | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
KR100402334B1 (ko) * | 2000-06-23 | 2003-10-22 | 환인제약 주식회사 | 알프로스타딜 외용제 |
HUP0402673A2 (hu) * | 2002-02-15 | 2005-04-28 | Nexmed (Holdings), Inc. | Erekciózavar kezelésére szolgáló prosztaglandin készítmény |
AU2003273291A1 (en) * | 2002-09-06 | 2004-03-29 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfuntion |
-
2004
- 2004-03-16 CA CA002519691A patent/CA2519691A1/en not_active Abandoned
- 2004-03-16 JP JP2006507236A patent/JP2006520788A/ja active Pending
- 2004-03-16 MX MXPA05010068A patent/MXPA05010068A/es not_active Application Discontinuation
- 2004-03-16 AU AU2004224459A patent/AU2004224459A1/en not_active Abandoned
- 2004-03-16 EP EP04757737A patent/EP1605913A2/en not_active Withdrawn
- 2004-03-16 KR KR1020057017710A patent/KR20050119136A/ko not_active Application Discontinuation
- 2004-03-16 US US10/803,101 patent/US20040241243A1/en not_active Abandoned
- 2004-03-16 CN CNA2004800098201A patent/CN1774237A/zh active Pending
- 2004-03-16 WO PCT/US2004/007981 patent/WO2004084861A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1774237A (zh) | 2006-05-17 |
EP1605913A2 (en) | 2005-12-21 |
CA2519691A1 (en) | 2004-10-07 |
WO2004084861A2 (en) | 2004-10-07 |
AU2004224459A1 (en) | 2004-10-07 |
WO2004084861A3 (en) | 2005-01-27 |
JP2006520788A (ja) | 2006-09-14 |
KR20050119136A (ko) | 2005-12-20 |
US20040241243A1 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE209856T1 (de) | Zusammensetzung und verfahren zur behandlung der erektilen disfunktion des penis | |
PT1161234E (pt) | Tratamento de hipertensao pulmonar por inalacao de prostaglandinas benzindeno | |
EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
CY1109558T1 (el) | Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων | |
GEP20063982B (en) | Use of prostaglandin compositions with male persons for treatment of erectile dysfunction | |
BR0213521A (pt) | Composto, composição farmacêutica, agente farmacêutico, uso do composto, e, métodos para antagonizar um receptor de hormÈnio que concentra melanina em um mamìfero, para prevenir ou tratar uma doença causada por um hormÈnio que concentra melanina em um mamìfero, para prevenir ou tratar a obesidade em um mamìfero, para suprimir a entrada de alimento em um mamìfero, para prevenir ou tratar a depressão em um mamìfero, para prevenir ou tratar a ansiedade em um mamìfero e para produzir o composto | |
BRPI0418245B8 (pt) | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes | |
BE2012C040I2 (es) | ||
MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
DE602005013793D1 (de) | Thiazolderivate mit vap-1-hemmender wirkung | |
MXPA05010068A (es) | Promocion de la angiogenesis por composiciones de prostaglandina y metodos. | |
IS2367B (is) | Imídasólafleiður til að stilla natríumgöng | |
DE60226517D1 (de) | Dipeptidyl peptidase iv inhibitoren zur senkung der chronische gewichtszunahme | |
MXPA04011835A (es) | Tratamiento de combinacion para la depresion y ansiedad. | |
HUP0302436A2 (hu) | Antidepresszáns gyógyszerek által kiváltott szexuális rendellenességek kezelése apomorfinnal | |
EA200200765A1 (ru) | Способ уменьшения или прекращения курения | |
BR0010699A (pt) | Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários | |
SE0004462D0 (sv) | Novel method and use | |
MY134074A (en) | Pharmaceutical composition comprising gamma-butyrobetaine for treatment of impotence | |
SE0301947D0 (sv) | New method and uses | |
WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
EA200300217A1 (ru) | Способ сокращения или прекращения курения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |